EMEA-003541-PIP01-23 - paediatric investigation plan
anti-alpha-synuclein recombinant humanised monoclonal antibody
PIPHuman
Key facts
- Active Substance
- anti-alpha-synuclein recombinant humanised monoclonal antibody
- Therapeutic area
- Nervous system disorders
- Decision number
- P/0067/2024
- PIP number
- EMEA-003541-PIP01-23
- Pharmaceutical form(s)
- All pharmaceutical forms
- Condition(s) / indication(s)
- Treatment of Parkinson's disease
- Route(s) of administration
- All routes of administration
- Contact for public enquiries
UCB Pharma S.A.
E-mail: UCBCares.IE@ucb.com
Tel. +353 1463 2371- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date